HA-Paclitaxel Conjugate Patent for Treatment of Mesothelioma
Summary
USPTO granted Patent US12605355B2 to Fidia Farmaceutici S.p.A. covering HA-paclitaxel conjugate compositions for loco-regional treatment of malignant mesothelioma. The patent, with 13 claims, covers malignant pleural, pericardial, and peritoneal mesothelioma applications, with priority dating to the April 7, 2021 filing.
“HA-paclitaxel conjugate for use in the loco-regional treatment of the mesothelioma, i.e., the malignant pleural mesothelioma, pericardial mesothelioma and peritoneal mesothelioma, preferably malignant pleural mesothelioma, and relative pharmaceutical compositions are described.”
What changed
USPTO issued Patent US12605355B2 to Fidia Farmaceutici S.p.A. for an HA-paclitaxel conjugate designed for loco-regional treatment of mesothelioma, including malignant pleural, pericardial, and peritoneal forms. The patent includes 13 claims covering the conjugate composition and associated pharmaceutical formulations.
Fidia Farmaceutici gains exclusive IP rights to this therapeutic application in the United States. Competitors developing similar locoregional paclitaxel-based treatments for mesothelioma should review the claim scope for potential freedom-to-operate considerations. The patent's issuance may affect licensing negotiations and R&D investment decisions in this therapeutic area.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HA-paclitaxel conjugate for treatment of mesothelioma
Grant US12605355B2 Kind: B2 Apr 21, 2026
Assignee
Fidia Farmaceutici S.p.A.
Inventors
Carlo Pizzocaro, Antonio Rosato
Abstract
HA-paclitaxel conjugate for use in the loco-regional treatment of the mesothelioma, i.e., the malignant pleural mesothelioma, pericardial mesothelioma and peritoneal mesothelioma, preferably malignant pleural mesothelioma, and relative pharmaceutical compositions are described.
CPC Classifications
A61K 31/337 A61K 47/61 A61K 9/0019 A61P 35/00
Filing Date
2021-04-07
Application No.
17916645
Claims
13
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.